Silvan Tuerkcan
Stock Analyst at JMP Securities
(3.71)
# 788
Out of 5,041 analysts
174
Total ratings
48.24%
Success rate
8.18%
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $20 → $15 | $7.25 | +106.90% | 13 | Oct 23, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Market Outperform | $33 | $25.86 | +27.61% | 12 | Oct 6, 2025 | |
| BNTC Benitec Biopharma | Reiterates: Market Outperform | $20 | $15.81 | +26.50% | 13 | Sep 24, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Market Outperform | $12 → $6 | $2.44 | +145.91% | 7 | Sep 22, 2025 | |
| PHR Phreesia | Maintains: Market Outperform | $30 → $34 | $23.79 | +42.92% | 1 | Sep 8, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Market Outperform | $41 → $45 | $28.64 | +57.15% | 2 | Sep 8, 2025 | |
| EXEL Exelixis | Reiterates: Market Outperform | $50 | $38.03 | +31.48% | 23 | Jul 29, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Market Outperform | $86 | $67.60 | +27.22% | 16 | Jun 27, 2025 | |
| NUVB Nuvation Bio | Reiterates: Market Outperform | $6 | $4.56 | +31.58% | 3 | Jun 25, 2025 | |
| SLDB Solid Biosciences | Reiterates: Market Outperform | $15 | $5.71 | +162.70% | 3 | Jun 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $5 → $6 | $4.96 | +20.97% | 13 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $10 → $6 | $5.44 | +10.29% | 3 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.80 | +136.84% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $120 | $27.99 | +328.72% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $7.87 | +128.86% | 4 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $17 | $2.02 | +741.58% | 5 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $6.16 | - | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $4 | $1.32 | +203.03% | 1 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $6.92 | +203.47% | 10 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.85 | - | 12 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $3.43 | +74.92% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $199.10 | +40.63% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $9.86 | +82.56% | 1 | Jan 26, 2023 |
Terns Pharmaceuticals
Oct 23, 2025
Maintains: Market Outperform
Price Target: $20 → $15
Current: $7.25
Upside: +106.90%
Intellia Therapeutics
Oct 6, 2025
Upgrades: Market Outperform
Price Target: $33
Current: $25.86
Upside: +27.61%
Benitec Biopharma
Sep 24, 2025
Reiterates: Market Outperform
Price Target: $20
Current: $15.81
Upside: +26.50%
Jasper Therapeutics
Sep 22, 2025
Maintains: Market Outperform
Price Target: $12 → $6
Current: $2.44
Upside: +145.91%
Phreesia
Sep 8, 2025
Maintains: Market Outperform
Price Target: $30 → $34
Current: $23.79
Upside: +42.92%
IDEAYA Biosciences
Sep 8, 2025
Maintains: Market Outperform
Price Target: $41 → $45
Current: $28.64
Upside: +57.15%
Exelixis
Jul 29, 2025
Reiterates: Market Outperform
Price Target: $50
Current: $38.03
Upside: +31.48%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $86
Current: $67.60
Upside: +27.22%
Nuvation Bio
Jun 25, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $4.56
Upside: +31.58%
Solid Biosciences
Jun 6, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $5.71
Upside: +162.70%
May 29, 2025
Maintains: Market Outperform
Price Target: $5 → $6
Current: $4.96
Upside: +20.97%
May 20, 2025
Maintains: Market Outperform
Price Target: $10 → $6
Current: $5.44
Upside: +10.29%
May 15, 2025
Reiterates: Market Outperform
Price Target: $9
Current: $3.80
Upside: +136.84%
May 9, 2025
Downgrades: Market Perform
Price Target: $120
Current: $27.99
Upside: +328.72%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $7.87
Upside: +128.86%
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $17
Current: $2.02
Upside: +741.58%
Mar 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $6.16
Upside: -
Jan 8, 2025
Initiates: Market Outperform
Price Target: $4
Current: $1.32
Upside: +203.03%
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $6.92
Upside: +203.47%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.85
Upside: -
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $3.43
Upside: +74.92%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $199.10
Upside: +40.63%
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $9.86
Upside: +82.56%